Beirne Wealth Consulting Services LLC Boosts Stake in Altimmune, Inc. $ALT

Beirne Wealth Consulting Services LLC grew its position in shares of Altimmune, Inc. (NASDAQ:ALT) by 16.3% during the second quarter, Holdings Channel reports. The fund owned 342,458 shares of the company’s stock after purchasing an additional 48,000 shares during the period. Beirne Wealth Consulting Services LLC’s holdings in Altimmune were worth $1,325,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ALT. Kingswood Wealth Advisors LLC purchased a new position in shares of Altimmune during the 2nd quarter worth approximately $40,000. Headland Capital LLC purchased a new position in shares of Altimmune during the 1st quarter worth approximately $50,000. Geneos Wealth Management Inc. purchased a new position in shares of Altimmune during the 1st quarter worth approximately $50,000. Keudell Morrison Wealth Management purchased a new position in shares of Altimmune during the 2nd quarter worth approximately $63,000. Finally, E Fund Management Co. Ltd. grew its holdings in shares of Altimmune by 20.3% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,427 shares of the company’s stock worth $67,000 after acquiring an additional 2,268 shares during the period. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Stock Performance

Shares of ALT opened at $4.06 on Wednesday. The business’s fifty day simple moving average is $3.81 and its two-hundred day simple moving average is $4.57. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.09. Altimmune, Inc. has a 12 month low of $2.90 and a 12 month high of $11.16. The company has a market cap of $358.34 million, a price-to-earnings ratio of -3.44 and a beta of 0.07.

Altimmune (NASDAQ:ALT) last issued its earnings results on Tuesday, August 12th. The company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.05. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%.The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Research analysts anticipate that Altimmune, Inc. will post -1.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a report on Wednesday, October 8th. JMP Securities cut their price target on Altimmune from $25.00 to $15.00 and set a “market outperform” rating on the stock in a research note on Thursday, July 10th. B. Riley cut their price target on Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. The Goldman Sachs Group upgraded Altimmune to a “strong sell” rating in a research note on Thursday, July 10th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Monday, October 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $17.40.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.